Ask in any UK aesthetics group whether a clinic needs its own FCA licence to offer instalments and you will have six confident replies within the hour. Some say authorisation is essential. Some say the requirement was scrapped in July. Some say the lender handles everything. One will mention a colleague who was fined, without naming a regulator.
The answers contradict each other for two reasons. The rules genuinely changed on 15 July 2026, and the correct answer depends on which product the clinic is actually offering. That gap between what practitioners believe and what the rules say is where most clinic finance myths live.
What follows sets out five of the common myths about offering finance in aesthetic clinics, with the regulatory position behind each. These are not marketing objections. They are common misconceptions about finance that either stop capable clinics offering something their clients already expect, or lead them to offer it in a way that breaches rules they did not know applied to them.
Myth one — every clinic needs its own FCA authorisation
Introducing a client to a lender is not a neutral administrative act. It is a regulated activity called credit broking, set out in article 36A of the Regulated Activities Order. Carrying it out with no permission and no cover is a criminal offence rather than a compliance slip, which is why the myth persists in the first place. The caution is well founded. The conclusion drawn from it usually is not.
What changed on 15 July 2026
The FCA began regulating Deferred Payment Credit on that date. DPC is the regulator’s term for interest-free credit repayable in twelve or fewer instalments within twelve months, provided by a lender who is not the business supplying the goods or services. Lenders now need authorisation or temporary permission, must carry out creditworthiness and affordability assessments, must give pre-contract information, and clients gain access to the Financial Ombudsman Service. The regulator’s firm-facing guidance sets out the regime (https://www.fca.org.uk/firms/regulating-buy-now-pay-later), and the final rules sit in policy statement PS26/1 (https://www.fca.org.uk/publications/policy-statements/ps26-1-regulation-deferred-payment-credit).
The part almost every summary skipped: the same legislation inserted a new exemption into the Regulated Activities Order covering merchants who broker DPC. The FCA’s own overview of PS26/1 states the position directly — merchants offering their own DPC agreements are not brought into regulation, and nor is the broking of DPC agreements.
For that specific product, a clinic introducing clients does not need its own permission.
Where the exemption stops
The exemption is tied to the product, not to the business. Interest-bearing agreements, and agreements running beyond twelve months, are ordinary regulated consumer credit and always have been. The DPC merchant exemption does not reach them. Introducing a client to one of those is credit broking, and it requires either the clinic’s own FCA authorisation or cover under an authorised firm’s permissions.
Most aesthetic clinic finance options in this sector take the second route. Payl8r, the lender behind Faces Finance, is authorised and regulated by the FCA under firm reference number 675283 and onboards clinics as Introducer Appointed Representatives under its own permissions (https://www.payl8r.com/merchants/introducer-appointed-representative/). The principal firm is accountable for the regulated credit activity its IARs carry out. Any lender’s status and permissions can be checked directly on the FCA Financial Services Register (https://register.fca.org.uk/s/).
The practical consequence is that “do I need FCA permission for buy now pay later aesthetics” has no single answer. It depends on whether the plan charges interest and how long it runs. A clinic whose lender offers both an interest-free short-term product and longer interest-bearing terms needs cover for the second even though the first sits outside the requirement.
What appointed representative status actually obliges you to do
IAR status is cover, not exemption from conduct. It brings training requirements, an approved-materials rule, restrictions on how and where finance can be promoted, and oversight by the principal firm. Practitioners who treat approval as the finish line tend to run into difficulty at the advertising stage, covered under myth four.
Myth two — the merchant fee means every financed booking loses money
The fee is real and it is unavoidable. It comes off every financed transaction whether that booking was one the clinic would have won anyway or one it would have lost. Across the wider market, merchant fees for instalment products typically sit somewhere from 1.5% of transaction value, against roughly 1% to 3% for card payments. Rates vary by lender, sector and volume, so the only figure that means anything is the current one in your own agreement.
The error is treating that fee as a loss rather than as a cost with a break-even point. The threshold is easy to calculate: divide the contribution on a treatment by the fee on that treatment, and the result is the number of financed bookings needed before one genuinely new booking pays for all of them. For most mid-to-high value plans the answer lands around one in fifteen. The worked example, with numbers, is set out in The Revenue Maths Behind Buy Now, Pay Later (https://facesconsent.com/blog/the-revenue-maths-behind-buy-now-pay-later/).
Two factors pull in the opposite direction to the fee, and both are routinely left out of the comparison.
The first is cash timing. Where aesthetic treatment payment plans are run in-house, with the clinic taking a deposit and chasing the balance, the practitioner is acting as an unpaid credit controller. Money arrives late, some never arrives, and staff hours disappear into pursuing it. Under a third-party arrangement the lender pays the treatment value and carries both the repayment relationship and the default risk. For a sole trader ordering stock ahead of a busy fortnight, that timing difference decides whether the stock can be ordered at all.
The second is plan completion. A client who cannot fund a three-session course books one session, gets a partial result and does not rebook. Split payment options for treatments let the same client commit to the full course and reach the outcome the plan was designed to produce. That is a completed course plus a client more likely to return, and almost no clinic measures it.
Myth three — finance pushes clients into treatments they cannot afford
This one deserves a proper answer rather than a dismissal, because the underlying concern is legitimate and the FCA’s own research supports it. Its Financial Lives work found around 10.9 million UK adults used unregulated instalment credit in the twelve months to May 2024, and that roughly 30% of users were adults with low financial resilience (https://www.fca.org.uk/news/press-releases/protections-help-buy-now-pay-later-borrowers-navigate-financial-lives).
That is an argument for how finance is offered, not against offering it.
Since 15 July 2026, affordability and creditworthiness assessment is mandatory for DPC, at every use and every purchase value, and lenders sit under the Consumer Duty. Interest-bearing agreements were already subject to those obligations. The assessment is not a formality standing between the clinic and a booking. It is the mechanism that makes patient finance for aesthetic treatments defensible, and it works only if a decline is treated as an outcome rather than an obstacle.
Where affordability is the barrier, a client can reasonably reapply with a larger deposit or a smaller order value, which turns a dead end into a smaller booking. What it must not become is a search for a route around an assessment that has done exactly what it exists to do.
The practitioner’s part is separate and comes first. Clinical indication, then price, then payment method, in that order. Presenting finance for cosmetic procedures as a way to fund a clinically appropriate plan is legitimate. Using the monthly figure to move a client to a larger plan than the assessment called for is not, and it fails the advertising rules as well as the clinical ones.
One point worth confirming with your own lender rather than assuming: whether applications are assessed by soft search. A soft search leaves no hard footprint on the client’s credit file. Missed repayments on a live agreement are a separate matter and can affect future borrowing.
Myth four — finance can be advertised the same way treatments are
This is where clinics most often go wrong, because two separate rulebooks apply to the same Instagram post.
The financial promotion layer
A communication inviting someone to take credit is a financial promotion. Under the Financial Services and Markets Act, an unauthorised business cannot issue one unless it is approved by an authorised firm or an exemption applies. Introducer Appointed Representatives are generally permitted to promote in non-real time only — social posts, website banners, email campaigns and in-clinic posters — and only using wording that follows the lender’s advertising guidelines.
What triggers the extra requirements is cost information. Under the FCA’s consumer credit rules, a promotion that states a rate of interest or an amount relating to the cost of credit must carry a representative example, and that example must be given no less prominence than the figure that triggered it (https://handbook.fca.org.uk/handbook/conc3/conc3s5). A monthly repayment figure counts. A genuine 0% APR offer presented as such is treated differently under those rules, which is precisely why clinics should not make the call themselves. Where the lender supplies approved wording, use it as written.
A neutral statement that instalment options are available at booking generally sits outside the trigger. “From £24 a month” does not. That distinction is the single most useful thing to hold on to when offering finance in beauty clinics and drafting your own social content.
The CAP Code layer
Advertising for cosmetic interventions must not trivialise the procedure, exploit insecurities or apply undue pressure, as the ASA sets out in its guidance on social responsibility in cosmetic interventions (https://www.asa.org.uk/advice-online/cosmetic-interventions-social-responsibility.html). This is being actively enforced. Following a targeted monitoring sweep of UK cosmetic advertisers, the ASA ruled against six liquid BBL advertisements for irresponsibly pressuring consumers into booking, trivialising risk or exploiting body image insecurities, and stated it expects a high level of caution when promoting procedures that carry significant risk.
Attaching a countdown or a limited-time frame to a buy now pay later for aesthetics offer combines a pressure tactic with a credit product. It is the riskiest thing a clinic can post, because it can breach both rulebooks in a single graphic. The workable rule is to promote availability and never urgency. The wider position on what can and cannot be said in aesthetic advertising is covered in Advertising Botox in the UK: What You Can Say (https://facesconsent.com/blog/advertising-botox-in-the-uk-what-you-can-say/).
Myth five — finance only applies to treatments
Clinics tend to think about instalments purely as a client-facing tool, which leaves the other half of the use case unexamined.
Course fees are a genuine bottleneck in this industry. Foundation and advanced qualifications routinely run to four figures, and capable candidates postpone by a year or drop out of the pipeline entirely because the fee lands as a single payment. Finance for training courses removes that timing problem in the same way instalments remove it in the consultation room. For an academy it fills cohorts that would otherwise run under capacity. For a practitioner it is the difference between qualifying this quarter and waiting until next year.
The mechanics are the same on both sides of the business. Finance for aesthetic training sits under the same permissions structure, the same affordability assessment and the same advertising restrictions as finance for treatments. An academy promoting training course payment options is subject to the financial promotion rules exactly as a clinic promoting treatment instalments is, and the CAP Code’s cosmetic interventions provisions do not disappear because the audience is professional rather than public. Academies listed on Faces can offer instalments on training courses and online courses through the same route clinics use.
What to check before you decide
Most finance for treatments myths trace back to one confusion: treating “finance” as a single product when the rules divide it into at least two, with different permission requirements, different regulatory histories and, since July, different exemptions.
Sorting financing myths and facts for your own clinic takes four checks rather than a research project.
Confirm which product your lender is offering, and whether it charges interest or runs beyond twelve months. Confirm on the FCA Register that the lender holds the permissions it claims. Confirm in writing whether you are covered as an Introducer Appointed Representative, and for which activities. And confirm what you are permitted to publish, in which channels, using whose wording.
Clinics that settle those four points once rarely revisit them. Clinics that leave them open tend to discover the answer at the point where it costs something.
Getting the permissions question settled
If the only thing stopping your clinic offering instalments is uncertainty about permissions, that is a question with an answer rather than a reason to wait.
Register for Faces Finance from your dashboard: open Finance Hub, select Register, and upload your current insurance, training certificate and photo ID. Approval typically takes 24 to 48 business hours, and IAR onboarding, approved promotional wording and the compliance side are handled through the lender rather than by the clinic. Before your next package goes on the price list, check the live merchant rate in Finance Hub and run the break-even calculation against your own contribution figures.
FAQs
Does a clinic carry the risk if a client stops paying?
No. Under a third-party arrangement the lender pays the treatment value to the clinic and takes on both the repayment relationship and the default risk. That transfer is a large part of what the merchant fee buys. In-house instalment arrangements are a different proposition entirely, and the risk stays with the clinic.
Can a clinic post “0% finance available” on social media?
Only within the financial promotion rules and using the lender’s approved wording. A genuine 0% APR offer presented as such is treated differently from a promotion quoting a monthly figure, but the assessment is not one a clinic should make independently. Adding any time limit or countdown to a finance offer also risks breaching CAP rules on pressure in cosmetic interventions advertising.
Did the July 2026 changes remove the need for clinics to hold permissions?
For interest-free credit repayable in twelve or fewer instalments within twelve months, most merchants are exempt from credit broking authorisation. For interest-bearing agreements and anything running longer, nothing changed and permission or appointed representative cover is still required.
Does offering finance affect what a clinic can charge?
Most merchant agreements prohibit charging financed clients more than cash clients, and differential pricing by payment method carries consumer credit implications. Check the agreement before building a surcharge into your pricing.
What happens if a client is approved but changes their mind?
Approval and drawdown are separate events. Agreement terms typically begin when treatment is completed and the confirmation code is entered rather than at approval, which leaves room to amend a plan beforehand. The exact sequence varies by lender and should be confirmed directly.